Corient Private Wealth
ABEO icon

Corient Private Wealth’s Abeona Therapeutics ABEO Stock Holding History

Corient Private Wealth’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,416
Closed -$127K – 2552
2025
Q2 		$127K Buy
+22,416
New +$128K ﹤0.01% 2303
2025
Q1 		– Sell
-22,416
Closed -$192 – 2276
2024
Q4 		$192 Hold
22,416
– – ﹤0.01% 2350
2024
Q3 		$142K Buy
22,416
+12
+0.1% +$63 ﹤0.01% 2278
2024
Q2 		$95K Buy
22,404
+8,502
+61% +$43.4K ﹤0.01% 2218
2024
Q1 		$101K Hold
13,902
– – ﹤0.01% 2186
2023
Q4 		$69.6K Hold
13,902
– – ﹤0.01% 2179
2023
Q3 		$58.5K Hold
13,902
– – ﹤0.01% 2068
2023
Q2 		$56K Buy
+13,902
New +$48.6K ﹤0.01% 2015

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Corient Private Wealth's ABEO Position: Q3 2025 in Review

Corient Private Wealth sold out of Abeona Therapeutics (ABEO) in Q3 2025, closing a stake of 22,416 shares — an estimated $127K sold.

Corient Private Wealth first reported a position in ABEO in Q2 2023 and held it in 8 quarters. The position peaked at $142K in Q3 2024. 100 funds tracked by Wall St. Rank hold ABEO as of Q3 2025.

  • Corient Private Wealth reported no remaining Abeona Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Corient Private Wealth sold 22,416 Abeona Therapeutics shares in Q3 2025, an estimated $127K.
  • Corient Private Wealth first reported a position in Abeona Therapeutics in Q2 2023 and held it in 8 quarters.
  • Corient Private Wealth's Abeona Therapeutics position peaked at $142K in Q3 2024.
  • 100 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2025.

Based on Corient Private Wealth's 13F filing for Q3 2025, filed 14 Nov 2025.